Endothelial Monocyte-activating Polypeptide-II as an Endothelial Dysfunction Marker and Its Relation to the Oxidative Stress in Egyptian Sickle Patients
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
- 主要终点
- Oxidative stress markers
研究概览
简要总结
This study objectives to assess the role of endothelial monocyte-activating polypeptide II (EMAP II) as a marker of endothelial dysfunction and disturbed angiogenesis in sickle cell disease and to identify its correlation With the oxidative status.
详细描述
Study design:
Screening/Baselie Phase
-
Detailed medical history with special emphasis on demographic data, transfusion and chelation therapy, disease modifying therapy
-
Thorough clinical examination
-
Laboratory investigations to be done will include:
-
Liver function test
-
Marker of hemolysis
-
Serum ferritin .
-
Complete blood count(CBC)
-
Hemoglobin electrophoresis
-
Determination of serum levels of EMAP II
-
Lipid Peroxidation (Malondialdehyde Concentration.), Superoxide Dismutase activity, Catalase activity, Glutathione Peroxidase activity, Glutathione Reductase activity, Vitamin E concentration, GSH
The patients under investigations will receive vitamin E supplementation for three months
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with sickle cell disease as confirmed by qualitative and quantitative analysis of hemoglobin using high performance liquid chromatography (HPLC) at their steady state.
排除标准
- •Patients with any inflammatory condition within one month prior to enrollment.
研究组 & 干预措施
vitamin E supplementation
vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
干预措施: Vitamin E (Drug)
结局指标
主要结局
Oxidative stress markers
时间窗: Two years
次要结局
- Endothelial monocyte-activating polypeptide II(Two year)
研究者
Fatma Soliman Elsayed Ebeid, MD
Professor of Pediatrics
Ain Shams University